Login| Sign Up| Help| Contact|

Patent Searching and Data


Matches 1 - 50 out of 1,379

Document Document Title
WO/2019/177099A1
Provided is a method for evaluating a test sample, said method making it easy to evaluate whether a test sample has the effect of suppressing cytokine production in skin cells, wherein the cytokine production suppressing effect of the te...  
WO/2019/177902A1
The present disclosure relates to bifunctional compounds, which find utility as modulators of Burton's Tyrosine Kinase (BTK). In particular, the present disclosure is directed to bifunctional compounds. One end of a bifunctional compound...  
WO/2019/160889A1
Compounds of Formula (I) or pharmaceutically acceptable salts thereof are provided and methods involving compounds of Formula (I) as effective inhibitors of CDK8 and/or CDK19 are also provided.  
WO/2019/160890A1
The present application provides bifunctional compounds of Formula (Ia): (Ia), or an enantiomer, diastereomer, stereoisomer, or pharmaceutically acceptable salt thereof, which act as protein degradation inducing moieties for one or more ...  
WO/2019/154257A1
The present invention relates to steroid derivative regulators, a method for preparing the same, and uses thereof. Specifically, the present invention relates to a compound of formula (I), a preparation method therefor, a pharmaceutical ...  
WO/2019/154247A1
The present invention relates to steroid derivative regulators, a method for preparing the same, and uses thereof. Specifically, the present invention relates to a compound as shown in formula (I), a preparation method therefor, a pharma...  
WO/2019/126741A1
Provided herein are compounds of Formula (I-I): and pharmaceutically acceptable salts thereof; wherein p, R1, R3a, R2a, R11a, R11b, R6a, and R6b are defined herein. Also provided herein are pharmaceutical compositions comprising a compou...  
WO/2019/113494A1
Provided herein is a deuterated compound of Formula (I) Formula (I) or a pharmaceutically acceptable salt thereof, wherein R3a,R5, R6a, R6b, R17, R21a, R21b, Rm, Rn, R16a, R16 b, R7a, R7b, R12a, R12b, R11a R11b, R2a, R2b, R19, R4a, and R...  
WO/2019/090331A1
Provided is a method of forming a copper-containing complex, including contacting a sample containing copper with a compound of Formula (I): wherein R is -OH or -O-CH3. Also provided is a method of inhibiting enzymatic activity of a kina...  
WO/2019/020068A8
Disclosed are a crystalline or amorphous form of steroid derivative FXR agonist (formula I), and a preparation method therefor, and a crystalline composition and pharmaceutical composition comprising the crystalline or amorphous form, an...  
WO/2019/062924A1
Provided are a long-acting prodrug of entecavir and a preparation method and application thereof. The prodrug of entecavir has the structure shown in formula I, and the compound can be released slowly, continuously, and stably and conver...  
WO/2019/020067A1
The present invention falls within the field of pharmaceutical chemistry, and relates to a method for preparing a steroid derivative FXR agonist and the relevant intermediates. In particular, the present invention relates to a method for...  
WO/2019/020068A1
Disclosed are a crystalline or amorphous form of steroid derivative FXR agonist (formula I), and a preparation method therefor, and a crystalline composition and pharmaceutical composition comprising the crystalline or amorphous form, an...  
WO/2018/224736A3
The invention relates to compounds of formula (I) and pharmaceutically acceptable salts thereof wherein Rl to R4 are as defined in the claims. The invention further relates to their use as inhibitors of 17P-HSD1 and in treatment or preve...  
WO/2019/002015A1
The invention relates to novel steroidal 17-beta heteroaryl compounds as AKR1C3 inhibitors, to the use thereof for the treatment and/or prophylaxis of diseases and to the use thereof for the production of medicaments for treatment and/or...  
WO/2018/237350A1
The present disclosure relates to methods and novel intermediates useful in the preparation of a compound of formula I or pharmaceutically acceptable salt, hydrate, solvate or amino acid, sulfate or glucuronide conjugate, or prodrug ther...  
WO/2018/224736A2
The invention relates to compounds of formula (I) and pharmaceutically acceptable salts thereof (I) wherein R1 to R4 are as defined in the claims. The invention further relates to their use as inhibitors of 17β-HSD1 and in treatment or ...  
WO/2017/205964A8
Estrane-based and androstane-based aminosteroid derivatives are described herein. More specifically, the following piperazinyl-steroid compounds of Formula I, Formula II, Formula III, and Formula IV are described. The compounds display c...  
WO/2018/152171A1
The present invention provides compounds represented by Formula I, or pharmaceutically acceptable salts, prodrugs and esters thereof, (I). The invention also provides pharmaceutical compositions comprising these compounds and methods of ...  
WO/2018/129497A1
The present invention generally relates to a method of diagnosing, prognosing and treating prostate cancer patients. Particularly, the present invention relates to a method of selecting patients with castration resistant prostate cancer ...  
WO/2018/103626A1
The present invention relates to the field of medicine, and particularly relates to a water-soluble allopregnenolone derivative, a pharmaceutical composition comprising the same, and use thereof in prevention or treatment of central nerv...  
WO/2018/086241A1
The present invention relates to a pH-sensitive ketal-linked cholesterol-zinc phthalocyanine coordination complex and a preparation method therefor and application thereof in medicine. In particular, the present invention relates to the ...  
WO/2018/071544A1
This document relates to an abiraterone derivative, 2-(((3S,8R,9S,10R,13S,14S)-10,13-dimethyl-17-(pyridin-3-yl)- 2,3,4,7,8,9,10,11,12,13,14,15-dodecahydro-1H-cyclopenta[a]ph enanthren-3-yl)oxy)-2-oxoacetic acid (ABOA). This document also...  
WO/2018/068021A1
The present invention relates generally to compositions and methods for treating cancer and hypercortisolism. Provided herein are substituted steroidal derivative compounds and pharmaceutical compositions comprising said compounds. The s...  
WO/2018/054300A1
Provided is a crystalline form cholic acid derivative free alkali, a preparation method therefor and an application. The chemical name of the cholic acid derivative free alkali is (5R)-5-((2R)-2-((3R,5S,6R,7R,10S,13R)-6-ethyl-3,7-dihydro...  
WO/2018/050099A1
Provided is a panaxdiol-type ginsenoside derivative having a structure as shown in formula I or formula II. Also provided is the use thereof in the preparation of a drug for preventing and treating atherosclerosis. The panaxdiol-type gin...  
WO/2018/029223A1
A process for the synthesis of β-hydroxy 3-17-(1H-benzimidazol-1-yl)androsta-5,16-diene is described, a compound also known as Galeterone and used in the treatment of prostate cancer, having the formula (6).  
WO/2018/013615A1
Described herein are neuroactive steroids of Formula (I), Formula (V), or Formula (IX) or a pharmaceutically acceptable salt thereof; wherein each instance of R2, R3, R4, R5, R6, R7, R11a, R11b,R12, R16, R17, R19, and ----- are as define...  
WO/2018/013613A1
Described herein are neuroactive steroids or a pharmaceutically acceptable salt thereof. Such compounds are envisioned, in certain embodiments, to behave as GABA modulators. Also provided are pharmaceutical compositions comprising a comp...  
WO/2017/205964A1
Estrane-based and androstane-based aminosteroid derivatives are described herein. More specifically, the following piperazinyl-steroid compounds of Formula I, Formula II, Formula III, and Formula IV are described. The compounds display c...  
WO/2017/208132A1
A process for the synthesis of 3β-hydroxy-17-(1H-benzimidazol-1-yl)androsta-5,16-diene is described, a compound also known as Galeterone and used in the treatment of prostate cancer, having the formula (I) given below.  
WO/2017/202003A1
Disclosed is a compound of formula (I) as a glycogen phosphorylase inhibitor or a pharmaceutically acceptable salt or ester thereof, wherein formula (I) is as defined in the description. The effect of the compound on inhibiting glycogeno...  
WO/2017/199033A1
The invention relates to compounds of general formula (I): wherein: R1,R2, R3, R4, R5, R6 and Y are as defined herein. The compounds are intermediates in the synthesis of synthetic bile acids which are useful in the treatment of conditio...  
WO/2017/199039A1
The invention relates to a process for preparing a compound of general formula (Ia): wherein R2, Y, R4 and R5 are as defined herein. The invention also relates to certain compounds per se. The compounds are intermediates in the synthesis...  
WO/2017/170564A1
[Problem] To provide a novel DDS having SN-38 as the medicinal component. [Solution] An excellent SN-38 ester derivative with cancer cell proliferation inhibitory activity is provided which is effective in nanodrug production.  
WO/2017/149091A1
The invention relates to a process for the preparation of 11 -methylene steroids through selective olefination of the ketone at position 11. The resulting products are useful intermediates in the preparation of several pharmaceutically a...  
WO/2017/151910A2
Disclosed are methods of selective cysteine and seienocysteine modification on peptide/protein molecules under physiologically relevant conditions. The methods feature several advantages over existing methods of peptide modification, suc...  
WO/2017/140183A1
Provided are substituted steroids and a use thereof. In particular, the substituted steroids of the present invention are steroids as shown by formula (I), or a crystal form, a pharmaceutically acceptable salt, a prodrug, a stereoisomer,...  
WO/2017/133360A1
Provided in the present invention are a steroidal compound, a composition containing the same and a use thereof. Specifically, disclosed in the present invention are a steroidal compound as shown in formula (I) and a drug composition con...  
WO/2017/134087A1
Steroidic calixarene compounds according to formula (I): (I) wherein: ∙ R represents -(CH2)x-L-(CH2)y-Ster, wherein : ○ x and y are integers comprised between 0 and 2; ○ n is an integer comprised between 1 and 5; ○ L represents a...  
WO/2017/129125A1
The present invention relates to a compound represented by formula (I), a tautomer thereof or a pharmaceutically acceptable salt thereof, and relates to applications thereof in the preparation of drugs for treating FXR related diseases.  
WO/2017/106957A8
This invention provides lipid-linked prodrugs having structures as set out herein. Uses of such lipid-linked prodrug compounds for treatment of various indications, and methods for making and using lipid-linked prodrugs are also provided.  
WO/2017/120218A1
A combination therapy for the treatment of cancers refractory to anti-androgen therapy; particularly prostate cancer. The combination therapy includes a pharmaceutically effective amount of enzalutamide, bicalutamide, and/or abiraterone ...  
WO/2017/112904A1
The present invention relates generally to compositions and methods for treating cancer and hypercortisolism. Provided herein are substituted steroidal derivative compounds and pharmaceutical compositions comprising said compounds. The s...  
WO/2017/106957A1
This invention provides lipid-linked prodrugs having structures as set out herein. Uses of such lipid-linked prodrug compounds for treatment of various indications, and methods for making and using lipid-linked prodrugs are also provided.  
WO/2017/112909A1
The present invention relates generally to compositions and methods for treating cancer and hypercortisolism. Provided herein are substituted steroidal derivative compounds and pharmaceutical compositions comprising said compounds. The s...  
WO/2017/112902A1
The present invention relates generally to compositions and methods for treating cancer and hypercortisolism. Provided herein are substituted steroidal derivative compounds and pharmaceutical compositions comprising said compounds. The s...  
WO/2017/101789A1
The present invention provides a compound having the structure (I), and pharmaceutically acceptable salt, stereoisomer, solvate, polymorph, or prodrug thereof, and a method for preparing said compound; also provided is an application of ...  
WO/2017/062763A1
The present application provides a compound of formula I: or a pharmaceutically acceptable salt, solvate, or amino acid conjugate thereof, as described herein. The present invention relates generally to FXR modulators and to methods of m...  
WO/2017/029664A1
A novel delivery system for drugs, and especially macromolecules such as proteins or oligonucleotides through biological membranes is provided, and specifically delivery of siRNA. The delivery system comprises conjugation of the macromol...  

Matches 1 - 50 out of 1,379